

Ref: MHL/Sec&Legal/2020/72

Date: February 06, 2020

To,

**Head, Listing Compliance Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

**Head, Listing Compliance Department
National Stock Exchange of India Limited**

Exchange Plaza,
Plot No. C/1. G Block,
Bandra -Kurla Complex, Bandra (East),
Mumbai - 400051

Scrip Code: **542650**

Scrip Symbol: **METROPOLIS**

Dear Sir/Madam,

Sub: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations').

We wish to inform you that pursuant to the applicable provisions of SEBI Listing Regulations, the Board of Directors (the "**Board**") at its meeting held today i.e. February 06, 2020, *inter-alia* considered and approved the following:

a) The Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and nine months ended December 31, 2019 and Limited Review Report issued by BSR & Co. LLP.

b) The payment of Interim Dividend of Rs.8/- (Rupees Eight Only) per equity share of the face value of Rs. 2/- (Rupee Two Only) each for the financial year 2019-20. The interim dividend will be paid to the members whose names appears in the Register of Members / Register of beneficiaries as on the 'Record Date' i.e. Saturday, February 15, 2020. The Interim Dividend will be paid to the entitled shareholders within 30 days of declaration.

Accordingly, we enclose herewith the following:

1. Unaudited Standalone financial results along with the Limited Review Report.
2. Unaudited Consolidated financial results along with the Limited Review report.

The above information is also being made available on the website of the Company.


The aforesaid Board Meeting commenced at 2.00 pm and concluded at 5:30 pm.

We request you to kindly take the same on record and acknowledge the receipt of the same.

Thanking you.

Yours Faithfully,

For Metropolis Healthcare Limited


**Ameera Sushil Shah
Managing Director
(DIN: 00208095)**



METROPOLIS
The Pathology Specialist

INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 02

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

BSR & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on Unaudited Quarterly Standalone Financial Results and Standalone Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited ('the Company') for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 ("the Statement"). Attention is drawn to the fact that the standalone figures for the corresponding quarter ended 31 December 2018 and corresponding period from 1 April 2018 to 31 December 2018, as reported in these financial results have been approved by the Board of Directors, but have not been subjected to review, since the equity shares of the Company were listed on the stock exchanges during the quarter ended 30 June 2019.
2. This Statement, which is the responsibility of the Company's management and approved by Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Limited review report on Unaudited Quarterly Standalone Financial Results and Standalone Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm Registration No: 101248W/W-100022


Tarun Kinger
Partner

Membership No: 105003

ICAI UDIN: 20105003AAAAAC9234


Mumbai
06 February 2020

Metropolis Healthcare Limited
Unaudited Standalone Financial Results for the quarter and nine months ended 31 December 2019
(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine Months ended		Year ended
		31 December 2019 (Unaudited)	30 September 2019 (Unaudited)	31 December 2018 (Unaudited) (refer note 7)	31 December 2019 (Unaudited)	31 December 2018 (Unaudited) (refer note 7)	31 March 2019 (Audited)
1	Income						
	a) Revenue from operations	17,290.97	17,228.28	14,579.07	50,215.19	42,678.05	58,120.81
	b) Other income	178.49	98.47	-	359.67	626.72	2,052.32
	Total Income	17,469.46	17,326.75	14,579.07	50,574.86	43,304.77	60,173.13
2	Expenses						
	a) Cost of material consumed	4,264.67	4,266.08	3,342.31	12,478.97	10,427.03	13,907.64
	b) Laboratory testing charges	128.89	173.18	177.17	437.98	307.84	469.16
	c) Employee benefits expense	3,806.30	3,816.36	3,422.53	11,272.72	10,397.74	13,694.67
	d) Finance costs	183.64	166.83	7.96	496.20	33.37	51.83
	e) Depreciation and amortisation expense	815.21	749.88	409.95	2,236.77	1,115.55	1,543.57
	f) Other expenses	4,271.75	4,344.98	3,921.95	12,460.41	11,348.22	15,587.33
	Total Expenses	13,470.46	13,517.31	11,281.87	39,383.05	33,629.75	45,254.20
3	Profit before exceptional item and tax (1) - (2)	3,999.00	3,809.44	3,297.20	11,191.81	9,675.02	14,918.93
4	Exceptional items (refer note 4)	-	-	-	686.48	-	-
5	Profit before tax (3) - (4)	3,999.00	3,809.44	3,297.20	10,505.33	9,675.02	14,918.93
6	Tax expenses						
	Current tax	846.10	611.55	1,141.38	2,283.30	3,420.00	4,717.00
	Deferred tax (income) / expense	(76.94)	30.17	(124.41)	(7.50)	58.97	56.23
	Total tax expenses	769.16	641.72	1,016.97	2,275.80	3,478.97	4,773.23
7	Profit for the period / year (5) - (6)	3,229.84	3,167.72	2,280.23	8,229.53	6,196.05	10,145.70
8	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(5.44)	(116.06)	34.51	(114.04)	34.31	33.43
	Items that will be subsequently reclassified to profit and loss (net of tax)	-	-	81.40	-	-	-
	Other comprehensive income / (loss) for the period / year (net of tax)	(5.44)	(116.06)	115.91	(114.04)	34.31	33.43
9	Total comprehensive income (7) + (8)	3,224.40	3,051.66	2,396.14	8,115.49	6,230.36	10,179.13
10	Paid-up equity share capital (face value - Rs. 2 per share)	1,003.57	1,003.57	1,003.57	1,003.57	1,003.57	1,003.57
11	Other equity						40,536.83
12	Earnings per share (of Rs.2 each) basic - (Rs.) *	6.44	6.31	4.57	16.40	12.43	20.32
	Earnings per share (of Rs.2 each) diluted - (Rs.) *	6.42	6.30	4.57	16.37	12.40	20.28

(*not annualised)

See accompanying notes to the unaudited standalone financial results



METROPOLIS
The Pathology Specialist

INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 0

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Limited

NOTES:

- 1 These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited results were reviewed by the Audit Committee at their meeting held on 06 February 2020 and thereafter approved by the Board of Directors at their meeting held on 06 February 2020. The statutory auditors have expressed an unmodified review opinion.
- 3 The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (April 1, 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on April 1, 2019. The Company has adopted Ind AS 116 using the cumulative effect method for transitioning.
- 4 Exceptional items in the financial results for the nine month ended 31 December 2019 includes: -
 - a) provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and;
 - b) provision for Rs.350.00 Lakhs on account of certain old unreconciled balances.
- 5 Disclosure of segment - wise information is not applicable, as pathology services is the Company only business segment.
- 6 The Company completed an Initial Public Offer through an offer for sale by the selling shareholders of 1,36,85,095 equity shares of Rs.2 each at price of Rs. 880. The equity shares of the Company got listed on the BSE Limited and National Stock Exchange of India Limited on 15 April 2019. Expenses related to the offer are being borne by selling shareholders.
- 7 The standalone financial results for the quarter ended 31 December 2018 and nine months ended 31 December 2018 were not subjected to limited review by the Statutory auditors and are as prepared by the Company's management.
- 8 The Company have elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company have recognised Provision of Income Tax for the nine months ended 31 December 2019 and re-measured its Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the quarter ended 30 September 2019 and nine months period ended 31 December 2019.
- 9 The Company is in process of acquiring 51% shareholding of Shraddha Diagnostic Centre (I) Private Limited for providing diagnostic and pathological testing services in Ahmedabad, Gujarat as approved in Board Meeting held on 15 January 2020 to strengthen the presence of the Company in the state of Gujarat for purchase consideration of Rs. 936.30 lakhs. The same is expected to be closed within 3 months from the date of approval of the Board.
- 10 The Board of Directors of the Company have approved the interim dividend of Rs. 8 per equity share (Face value of Rs. 2 each) at the meeting held on 06 February 2020.
- 11 The results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited



Ameera Shah
Managing Director
DIN : 00208095

Place: Mumbai



METROPOLIS
The Pathology Specialist

INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-1A, Kothinor Mall, Vidyavihar (W), Mumbai - 400 070.

B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited review report on Unaudited Quarterly Consolidated Financial Results and Consolidated Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net (loss) after tax and total comprehensive loss of its joint venture for the quarter ended 31 December 2019 and year to date results for the period from 1 April 2019 to 31 December 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31 December 2018 and corresponding period from 1 April 2018 to 31 December 2018, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review since the equity shares of the Parent were listed on the stock exchanges during the quarter ended 30 June 2019.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes result of the entities as stated in Annexure I



B S R & Co (a partnership firm with
Registration No. BA61223) converted into
B S R & Co. LLP (a Limited Liability Partnership
with LLP Registration No. AAB-8181)
with effect from October 14, 2013

Registered Office:
5th Floor, Lodha Excelus
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011, India

Limited review report on Unaudited Quarterly Consolidated Financial Results and Consolidated Year-to-Date Results of Metropolis Healthcare Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The Statement includes the interim financial results of 6 (six) subsidiaries which have not been reviewed, whose interim financial results reflect total revenue of Rs.1,031.33 Lakhs and Rs. 3,187.52 Lakhs, total net (loss) after tax of Rs. 7.37 Lakhs and profit after tax of Rs. 74.82 Lakhs and total comprehensive income of Rs. 12.15 Lakhs and Rs. 79.11 Lakhs for the quarter ended 31 December 2019 and for the period from 1 April 2019 to 31 December 2019, respectively, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For B S R & Co. LLP

Chartered Accountants

Firm Registration No: 101248W/W-100022


Tarun Kinger
Partner

Membership No: 105003

ICAI UDIN: 20105003AAAAAD7254

Mumbai
06 February 2020

Annexure I

List of entities included in the consolidated financial results:

Sr No	Name of Entity	Relationship
1	Sudharma Metropolis Health Services Private Limited	Subsidiary
2	Bokil Golwilkar Metropolis Healthcare Private Limited	Subsidiary
3	Raj Metropolis Healthcare Private Limited	Subsidiary
4	Desai Metropolis Health Services Private Limited	Subsidiary
5	R.V. Metropolis Diagnostics & Health Care Centre Private Limited	Subsidiary
6	Micron Metropolis Healthcare Private Limited	Subsidiary
7	Dr. Patel Metropolis Healthcare Private Limited	Subsidiary
8	Lab One Metropolis Healthcare Services Private Limited	Subsidiary
9	Amin's Pathology Laboratory Private Limited	Subsidiary
10	Ekopath Metropolis Lab Services Private Limited	Subsidiary
11	Metropolis Healthcare Lanka (Pvt) Limited	Subsidiary
12	Metropolis Healthcare (Mauritius) Limited	Subsidiary
13	Metropolis Star Lab Kenya Limited	Subsidiary
14	Metropolis Healthcare Ghana Limited	Subsidiary
15	Metropolis Bramser Lab Services (Mtius) Limited	Subsidiary
16	Metropolis Healthcare (Tanzania) Limited	Subsidiary
17	Metropolis Histoxpert Digital Services Private Limited	Joint Venture



Metropolis Healthcare Limited

Statement of Consolidated Financial Results for the quarter and nine months ended 31 December 2019

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended			Nine Months Ended		Year ended
		31 December 2019 (Unaudited)	30 September 2019 (Unaudited)	31 December 2018 (Unaudited) (Refer Note 8)	31 December 2019 (Unaudited)	31 December 2018 (Unaudited) (Refer Note 8)	
1	Income						
	a) Revenue from operations	22,285.38	22,328.08	19,043.53	64,943.09	55,930.55	76,118.18
	b) Other income	218.95	196.74	222.35	549.54	751.49	821.32
	Total Income	22,504.33	22,524.82	19,265.88	65,492.63	56,682.04	76,939.50
2	Expenses						
	a) Cost of material consumed	5,232.36	5,268.30	4,262.59	15,319.20	12,966.91	17,351.02
	b) Laboratory testing charges	123.19	152.10	123.15	429.38	384.60	557.17
	c) Employee benefits expense	4,841.33	4,957.98	4,462.81	14,523.57	13,372.08	17,620.71
	d) Finance costs	239.58	190.97	18.56	606.73	45.75	53.11
	e) Depreciation and amortisation expense	1,055.91	928.92	530.13	2,812.30	1,461.42	2,006.61
	f) Other expenses	5,732.07	5,686.85	5,273.52	16,528.46	14,884.66	20,552.68
	Total Expenses	17,224.44	17,185.12	14,670.76	50,219.64	43,115.42	58,141.30
3	Profit before exceptional items, share of profit for equity accounted investees and income tax (1) - (2)	5,279.89	5,339.70	4,595.12	15,272.99	13,566.62	18,798.20
4	Exceptional Items (Refer note 5)	-	-	-	686.48	-	-
5	Profit before share of profit for equity accounted investees and tax (3) - (4)	5,279.89	5,339.70	4,595.12	14,586.51	13,566.62	18,798.20
6	Share of loss for equity accounted investees (net of tax)	-	(19.06)	(43.93)	(51.98)	(104.01)	(143.02)
7	Profit before tax (5) + (6)	5,279.88	5,320.64	4,551.19	14,534.53	13,462.61	18,655.18
8	Tax expenses						
	Current tax	1,173.52	976.26	1,497.55	3,371.84	4,584.59	6,309.03
	Deferred tax (income) / expense	(95.02)	31.35	(79.24)	(43.19)	0.19	(15.13)
	Total tax expenses	1,078.50	1,007.61	1,418.31	3,328.65	4,584.78	6,293.90
9	Profit for the period/year (7) - (8)	4,201.39	4,313.03	3,132.88	11,205.88	8,877.83	12,361.28
10	Other comprehensive income						
	Items that will not be reclassified subsequently to profit and loss (net of tax)	(8.26)	(176.84)	62.82	(173.51)	43.33	49.96
	Items that will be subsequently reclassified to profit and loss (net of tax)	8.11	(17.97)	107.82	0.56	140.11	89.32
	Other comprehensive (loss) / income for the period/year (net of tax)	(0.15)	(194.81)	170.64	(172.95)	183.44	139.28
11	Total comprehensive income (9) + (10)	4,201.24	4,118.22	3,303.52	11,032.93	9,061.27	12,500.56
12	Profit/ (loss) attributable to:						
	Owners of the Company	4,207.22	4,298.05	3,120.36	11,183.27	8,566.18	12,014.79
	Non-controlling interest	(5.83)	14.98	12.52	22.61	311.65	346.49
13	Other comprehensive (loss) / income attributable to:						
	Owners of the Company	(0.14)	(194.58)	169.55	(172.62)	183.00	138.14
	Non-controlling interest	(0.01)	(0.23)	1.09	(0.33)	0.44	-1.14
14	Total comprehensive income / (loss) attributable to:						
	Owners of the Company	4,207.08	4,103.47	3,289.91	11,010.65	8,749.18	12,152.93
	Non-controlling interest	(5.84)	14.75	13.61	22.28	312.09	347.63
15	Paid-up equity share capital (face value - Rs. 2 per share)	1,003.57	1,003.57	1,003.57	1,003.57	1,003.57	1,003.57
16	Other equity (including Non-controlling interest)						41,996.91
17	Earnings per share (Face value of Rs. 2 each) basic - (Rs.) *	6.38	8.57	6.26	22.29	17.18	24.06
	Earnings per share (Face value of Rs. 2 each) diluted - (Rs.) *	8.37	8.55	6.25	22.24	17.15	24.02

(*not annualised)

See accompanying note to the unaudited consolidated financial results



Amr



METROPOLIS
The Pathology Specialist

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 03

CIN: U73100MH2000PLC192798. Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-1A, Kohnoor Mall, Vidyavihar (W), Mumbai - 400 070.

Metropolis Healthcare Limited

NOTES:

- 1 These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The above unaudited results were reviewed by the Audit Committee at their meeting held on 6 February 2020 and thereafter approved by the Board of Directors at their meeting held on 6 February 2020. The statutory auditors have expressed an unmodified review opinion.
- 3 Metropolis Healthcare Limited (the 'Company' or the 'Parent'), and its subsidiaries (referred to collectively as the 'Group') and its joint venture are primarily involved in providing pathology and related healthcare services
- 4 The Group has adopted Ind AS 116, effective annual reporting period beginning 01 April 2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (01 April 2019). Accordingly, the Group has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on 01 April 2019. The Group has adopted Ind AS 116 using the cumulative effect method for transitioning
- 5 Exceptional items in the consolidated financial results for the nine months ended 31 December 2019 includes: -
 - a) provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and;
 - b) provision for Rs.350.00 Lakhs on account of certain old unreconciled balances.
- 6 Disclosure of segment-wise information is not applicable, as pathology services is the Group's only business segment.
- 7 The Company completed an Initial Public Offer through an offer for sale by the selling shareholders of 1,36,85,095 equity shares of Rs.2 each at price of Rs. 880. The equity shares of the Company got listed on the BSE Limited and National Stock Exchange of India Limited on 15 April 2019. Expenses related to the offer are being borne by selling shareholders.
- 8 The Consolidated financial results for the quarter ended 31 December 2018 and nine months ended 31 December 2018 were not subjected to limited review by the Statutory auditors and are as prepared by the Parents' management.
- 9 The Company has through its wholly owned subsidiary "Desai Metropolis Health Services Private Limited", has acquired 4 (four) Laboratories from: (i) Doctor's Clinical Laboratory (partnership firm), (ii) Iyer Pathology Laboratory (sole proprietary), (iii) Nagar Pathology Laboratory (sole proprietary) and (iv) Yash Clinical Laboratory (sole proprietary), for providing diagnostic and pathological testing services in Surat, Gujarat as on 30 September 2019 for purchase consideration of Rs. 1,800 lakhs payable in 3 tranches starting from 30 September 2019.
- 10 The Company is in process of acquiring 51% shareholding of Shraddha Diagnostic Centre (I) Private Limited for providing diagnostic and pathological testing services in Ahmedabad, Gujarat as approved in Board Meeting held on 15th January 2020 to strengthen the presence of the Company in the state of Gujarat for purchase consideration of Rs. 936.30 lakhs. The same is expected to be closed within three months from the date of approval of the Board.
- 11 The Board of Directors of the Company have approved the interim dividend of Rs. 8 per equity share (Face value of Rs. 2 each) at the meeting held on 06 February 2020.
- 12 The Company and its Indian subsidiary companies have elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company and certain subsidiary companies have recognised Provision of Income Tax for the nine months ended 31 December 2019 and re-measured its Deferred Tax basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the quarter ended 30 September 2019 and nine months period ended 31 December 2019.
- 13 The results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

For Metropolis Healthcare Limited

Ameera Shah
Managing Director
DIN:00208095

Place: Mumbai
Date: 06 February 2020



METROPOLIS
The Pathology Specialist

INNER HEALTH REVEALED

Metropolis Healthcare Limited

Registered Office: 250 D, Udyog Bhavan, Hind Cycle Marg, Worli, Mumbai - 400 030.

CIN: U73100MH2000PLC192798, Tel: +91-22-3399 3939 / 6650 5555.

Email: support@metropolisindia.com | Website: www.metropolisindia.com

Central Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.